Senators Alsobrooks and Wyden Press HHS on Drug-Trial Betting Markets

Two Democratic senators have formally asked the Department of Health and Human Services what safeguards exist around prediction markets that let traders bet on drug trial results and FDA approvals.

Sen. Angela Alsobrooks of Maryland and Sen. Ron Wyden of Oregon sent the letter to HHS, according to a copy obtained first by CNBC. The letter targets the newest and most sensitive corner of the event-contract boom: markets tied to clinical trial endpoints and regulatory decisions. HHS has not publicly responded. No enforcement action tied to these contracts has been reported to date.

What does the letter actually ask for?

The request is direct. The senators want HHS to lay out what protections, if any, govern event contracts where traders take positions on whether a drug clears a late-stage trial or wins FDA sign-off.

The question lands squarely on Kalshi. In July 2026, the prediction market platform launched a pilot program covering roughly a dozen FDA-related contracts. Users can bet on late-stage clinical trial endpoints and approval outcomes. Trading volumes for the drug-related contracts had not been reported as of early November 2026.

That volume gap matters. A market nobody uses is far easier to defend than one attracting serious money.

Why researchers are uneasy

The senators are not raising this in a vacuum. In October 2026, researchers from Boston University and other institutions warned that market odds could affect trial integrity and public confidence in outcomes.

Their concerns go beyond the ethics of gambling on a cancer drug. The researchers flagged possible effects on how trial participants behave, including adherence rates. Adherence is clinical shorthand for whether patients actually take the treatment as instructed. If participants know odds are moving on their trial, behavior could shift in ways that corrupt the data.

The researchers also pointed to public trust in regulatory processes. They singled out vaccines as an especially sensitive area, where skepticism already runs high.

Consumer advocacy group Public Citizen weighed in too. On November 2, 2026, it named betting on clinical trial outcomes its "Outrage of the Month."

Why drug trials differ from election markets

What makes these contracts different is information distribution. An election market draws on an outcome decided by millions of voters, in public. A clinical trial's relevant knowledge sits with a much smaller circle: the researchers running the study and the participants inside it.

That concentration is exactly why the safeguards question carries weight. Markets work best when information spreads out and resists monopolization, and a late-stage trial is close to the opposite of that ideal, which helps explain why the senators aimed their letter at the health department rather than treating this as a routine trading matter for market regulators.

What does this change for prediction markets?

Right now, not much operationally. The contracts keep trading. But three things will shape the outcome.

• Whether HHS answers publicly, and what it says about its authority over health-related event contracts.
• Whether Kalshi expands, holds steady or trims its FDA-related slate.
• Whether trading volume data surfaces, giving critics or defenders a concrete number to argue over.

Until then, the drug trial contracts sit in an uncomfortable middle ground: small enough to call an experiment, sensitive enough to draw two senators, academic researchers and a consumer watchdog into the same conversation.